Revenue
2020
2021
2022
2023
2024
2025
Foghorn Therapeutics Inc. (FHTX)
Price—Loading quote
Net income
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2019
2020
2021
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2018
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|---|---|
| Revenue | $30.9M | $22.6M | $34.2M | $19.2M | $1.3M | $430,000 | — |
| Research & development | $85.5M | $94.5M | $109.7M | $105.6M | $80.3M | $57.7M | $44.4M |
| Operating expenses | $117.3M | $125.3M | $142.1M | $136.4M | $102.1M | $69.0M | $51.1M |
| Operating income | −$86.4M | −$102.7M | −$107.9M | −$117.1M | −$100.7M | −$68.5M | −$51.1M |
| EBITDAderived | −$83.1M | −$99.6M | −$104.5M | −$113.8M | −$97.5M | −$67.2M | −$50.4M |
| Net income | −$74.3M | −$86.6M | −$98.4M | −$108.9M | −$101.3M | −$68.8M | −$51.1M |
| Basic EPSper diluted share | -$1.18 | -$1.58 | -$2.34 | -$2.62 | -$2.73 | -$6.23 | -$12.20 |
| Diluted EPSper diluted share | -$1.18 | -$1.58 | -$2.34 | -$2.62 | -$2.73 | -$6.23 | -$12.20 |
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Sep 23, 2024Form 4 · 10b5-1 | Costa CarlosChief People Officer | SellCommon Stock | 857 | $10.17 | $8.7K | 0 |
| Sep 20, 2024Form 4 · 10b5-1 | Costa CarlosChief People Officer | SellCommon Stock | 35.8K | $10.04 | $359.0K | 0 |
| Sep 18, 2024Form 4 · 10b5-1 | Costa CarlosChief People Officer | SellCommon Stock | 11.6K | $10.05 | $116.3K | 0 |
| Sep 17, 2024Form 4 · 10b5-1 | Costa CarlosChief People Officer | SellCommon Stock | 10.3K | $10.04 | $103.1K | 0 |
| Sep 16, 2024Form 4 · 10b5-1 | Costa CarlosChief People Officer | SellCommon Stock | 400 | $10.00 | $4.0K | 0 |